224 related articles for article (PubMed ID: 12574694)
1. Advances in the treatment of secondary pulmonary hypertension.
Maloney JP
Curr Opin Pulm Med; 2003 Mar; 9(2):139-43. PubMed ID: 12574694
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
3. [Pulmonary arterial hypertension and systemic sclerosis].
Launay D; Humbert M; Hachulla E
Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
[TBL] [Abstract][Full Text] [Related]
4. Bosentan for the treatment of portopulmonary hypertension.
Tempe DK; Datt V; Datta D
Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
[No Abstract] [Full Text] [Related]
5. Pulmonary arterial hypertension: combination therapy in the modern management era.
Sitbon O
Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
[No Abstract] [Full Text] [Related]
6. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
7. Combination drug therapy in the management of pulmonary arterial hypertension.
Kayser SR
Prog Cardiovasc Nurs; 2005; 20(4):177-82. PubMed ID: 16276142
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
[TBL] [Abstract][Full Text] [Related]
10. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
[TBL] [Abstract][Full Text] [Related]
11. [Bosentan and chronic thromboembolic pulmonary hypertension].
Tomás C; Callejas-Rubio JL; Ríos-Fernández R; Ortego-Centeno N
Med Clin (Barc); 2007 Nov; 129(16):639. PubMed ID: 18001681
[No Abstract] [Full Text] [Related]
12. [The combined use of sildenafil with epoprostenol in a patient with primary pulmonary hypertension].
Kayikçioğlu M; Can LH; Payzin S; Kültürsay H; Soydan I
Anadolu Kardiyol Derg; 2002 Sep; 2(3):262-4. PubMed ID: 12223337
[No Abstract] [Full Text] [Related]
13. Portopulmonary hypertension.
Nayak RP; Li D; Matuschak GM
Curr Gastroenterol Rep; 2009 Feb; 11(1):56-63. PubMed ID: 19166660
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Krishnan U; Krishnan S; Gewitz M
Pediatr Cardiol; 2008 Nov; 29(6):1082-6. PubMed ID: 18594787
[TBL] [Abstract][Full Text] [Related]
15. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
16. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
Park J; Song JH; Park DA; Lee JS; Lee SD; Oh YM
J Korean Med Sci; 2013 Aug; 28(8):1200-6. PubMed ID: 23960448
[TBL] [Abstract][Full Text] [Related]
18. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
[TBL] [Abstract][Full Text] [Related]
20. [Sildenafil as a substitute for subcutaneous prostacyclin in pulmonary hypertension].
Cea-Calvo L; Escribano Subías P; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
Arch Bronconeumol; 2003 Oct; 39(10):476-7. PubMed ID: 14533998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
